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Executive Summary 
 The African continent today faces a crisis of inadequate palliative care, in spite of the 
growing level of suffering of its citizens who are faced with debilitating diseases and injuries. Much 
of this problem stems from deeply ingrained attitudes towards opioids: while the American 
continent grapples with the effects of opioid overprescribing, physicians trained in Africa are taught 
that opioids are inappropriate for virtually all scenarios, and therefore they come to fear and avoid 
their use or simply remain untrained on them altogether. Patients fail to advocate for themselves out 
of submission to the doctor’s authority, governments remain apathetic to the situation, and as a 
result thousands of Africans die every year in agonizing and completely preventable pain. 
 Recognizing this growing problem, American Cancer Society (ACS) has partnered with 
African governments and hospice organizations to create an initiative known as “Treat the Pain.” 
The main focus of the program is on in-house production of an oral morphine solution that is cheap 
to make, simple to administer, and highly effective at treating pain. The program has been 
implemented in 5 different African countries (Uganda, Kenya, Rwanda, Nigeria, and Swaziland), and 
several other countries have expressed interest and are currently receiving “technical support” from 
ACS. Due to a scarcity of high-quality data, attempts at program evaluation have been limited and it 
is not known whether the initiative is having its intended effect. 
 This capstone represents a first attempt at utilizing the available information to determine 
whether countries implementing “Treat the Pain” have indeed increased their consumption of 
opioids, specifically morphine. Utilizing a United Nations report on opioid consumption, I have 
attempted to determine whether there is a difference in reported morphine consumption after the 
date of program implementation when compared to the years before, and also in comparison to 
countries not participating in the initiative. Using a time series regression and difference-in-
differences analysis, I found no statistically significant impact on morphine consumption due to 
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program implementation. Given that there are few instances of the program and that the morphine 
consumption data is deeply flawed, I recommend continued controlled implementation of the 
program, and emphasize improved data collection going forward. 
Introduction 
It is difficult for those living in the developed world to imagine a scenario where a loved one 
suffering with a debilitating and painful disease (such as cancer) would receive only acetaminophen 
or ibuprofen as a treatment for their pain. Yet this is the daily reality for many people living in low 
and middle income countries, and it reaches nearly epidemic proportions when considering the 
African continent specifically. A graphical depiction of worldwide opioid consumption (in morphine 
milligram equivalents per capita) in 2015 starkly reveals Africa’s anomalous behavior: 
Figure 1. Worldwide Opioid Consumption, 2015 
 
Source: https://ppsg.medicine.wisc.edu/  
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When repeating this map across multiple years, a similar pattern emerges: in any given year, 
different African countries might appear with a report of opioid consumption, but consistently at 
very low levels. It is also consistent that each year about half of African countries fail to make a 
report (i.e. “No data”). 
In spite of the inexpensive nature of palliative treatment options, specifically morphine, 
African governments and physicians appear irrationally averse to providing such treatment to their 
patients. Yet little has been done to acknowledge or address the problem, leaving many thousands of 
Africans with inadequate care. One rare exception to this tragedy has appeared in the form of a 
hospice organization in partnership with American Cancer Society (ACS), creating an initiative 
known as “Treat the Pain.” The concept focuses on increasing the supply of morphine, building 
prescriber awareness and knowledge of palliative care, and advocating to government organizations 
for improved access to pain treatments for those who are suffering. 
Analysis of the program to date has been difficult (mainly due to the scarcity of quality data 
on the African continent) and has focused largely on epidemiologic data to assess unmet need (ACS, 
2013). It is the purpose of this capstone to determine what impact the morphine production 
initiative may have had on morphine consumption in the countries where it has been implemented. 
Morphine consumption data from individual countries will be analyzed in the context of the date of 
ACS program implementation and compared to countries where the program has not yet been 
adopted. While this analysis certainly bears flaws, its intent is to elucidate whether ACS is in fact 
achieving its goal of improving morphine utilization and access, and if further expansion of the 
program should be considered. 
 
 
 
Page | 4  
 
Literature Review 
The Healthcare Situation in Africa 
The African continent faces a unique crisis of suffering in comparison to the rest of the 
world. Perhaps its most pressing issue is an overwhelming burden of HIV/AIDS: according to 
hiv.gov, 53 percent of all cases worldwide are in eastern and southern Africa (19.4 million people), 
and 17 percent of cases are in western and central Africa (6.1 million people) (U.S. DHHS, 2018). 
While access to antiretroviral treatment is improving through the efforts of international 
organizations, those afflicted with the disease are still subject to many of its unfortunate effects. 
Often overlooked are the painful side effects of AIDS, either from infection or cancer and resulting 
damage to organs and tissues of the body. Also on the rise in Africa is the incidence of cancer, 
which now surpasses malaria as a cause of death in Africans (635,400 cancer deaths v. 394,000 
malaria deaths in 2015) (Dent et al, 2017). Cancer treatments are even less accessible than 
antiretrovirals or antimalarials, meaning that the majority of cancer patients in Africa either die 
before receiving treatment, or they present at advanced stages of disease when tumors are 
disfiguring and extremely painful (Dent et al, 2017; Hannon, Breffni et al, 2016). 
 Access to palliative care services in most of Africa is similarly insufficient to meet the 
overwhelming need created by AIDS, cancer, and other diseases. Palliative care refers to the range of 
services employed to provide comfort and dignity to those suffering with a terminal or chronic 
illness that bears a high burden of pain (WPCA and WHO, 2014). In spite of the relatively 
inexpensive nature of palliative treatment options, various factors have led to the absence of such 
services from much of the African continent. 
Factors Influencing the Crisis 
 Perhaps the most apparent factor contributing to Africa’s palliative care crisis is the general 
scarcity of resources throughout much of the continent. This results in deficiencies across the entire 
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spectrum of healthcare, but palliative care is particularly hard hit because focusing on palliative care 
does not directly improve mortality measures (i.e. palliative care is not curative) (WPCA and WHO, 
2014; Knaul et al, 2018). Thus, in spite of the low cost of certain opioids, such as morphine, more 
resources are directed towards other inexpensive medications such as antihypertensives, antibiotics, 
antiepileptics, and antineoplastics. Meanwhile, donors to charitable organizations put emphasis on 
supplying more expensive treatments such as antiretrovirals for AIDS, antimalarials, and 
vaccinations (Shiffman, 2006). These organizations likewise pass over palliative care, in part because 
of a lack of attention to the issue, but also out of a reluctance to supply opioids due to the 
unfortunate American experience with such medications. Whereas the Western world largely 
grapples with opioid overprescribing, addiction, and overdose deaths, they cannot fathom a situation 
wherein increasing opioid supply might be beneficial. 
 The palliative care issue is not merely one of access to resources, however, but also of 
attitudes towards those resources. From the government level, only 6 out of 54 countries in Africa 
have a national policy on palliative care, and if official policies exist on proper handling and tracking 
of controlled substances, they are either poorly defined or overly restrictive (Knaul et al, 2018; 
Luyirika et al, 2016). Government disinterest is further exacerbated by international regulations 
governing the ordering and tracking of controlled substances. The 1961 Single Convention on 
Narcotic Drugs established an International Narcotics Control Board (INCB) that oversees the 
international trade of controlled substances, such as opioids (Davis and Anderson, 2010). Individual 
countries are required to submit reports to INCB of estimated needs for the coming year, and upon 
review, an ordering limit is established on how much opioid or other controlled substance the 
country can import or export (Davis and Anderson, 2010). In any given year, nearly half of all 
African countries will either report absolutely no need for opioids or fail to report at all, meaning 
that INCB will not allow them to import any opioids for the coming year (further 
Page | 6  
 
appeals/negotiations are possible) (Board of Regents, 2018). It should be noted that this 
phenomenon is completely unique to the African continent – in every other continent, nearly every 
country indicates at least some yearly need for opioids. Yet this unusual behavior of African 
governments consistently inspires little to no response either from the international community or 
from within the individual countries themselves. 
 Such opioid-antagonistic attitudes by governments are reflective of a similar reluctance held 
by prescribers and patients within these countries. Although opioids have been historically poorly 
supplied as previously mentioned, the truth is that even if supply were improved the medications 
would still not likely end up being prescribed to patients. This can mainly be attributed to a 
phenomenon known as “opiophobia,” defined as fearful prejudice against the prescribing and use of 
opioid medications, even if medically appropriate (Knaul et al, 2018). While this fear can be healthy 
in the context of illicit drug use or inappropriate prescribing practices, it is inhumane and even 
dangerous when there is legitimate suffering. The origins of opiophobia from the prescriber 
perspective come from a lack of training on what constitutes a legitimate indication for the use of 
opioids, the appropriate dosing of these drugs, or necessary monitoring parameters (Knaul et al, 
2018). It is also generally true that current educational models in these nations describe opioids as 
always being dangerous because of their potential to cause both addiction and life-threatening side 
effects. From the patient’s perspective, a similar fear of the medication exists along with the stigma 
of being viewed as an addict (Knaul et al, 2018). Culturally, the African patient is often a poor self-
advocate because the doctor is viewed as an authority figure (Knaul et al, 2018). This means that if 
the doctor does not recommend treatment of pain, then it is not the patient’s responsibility to 
request this of the doctor. It is also not uncommon for patients to have very little experience 
interacting with doctors practicing modern medicine, and so they do not know how to handle the 
encounter or what to expect from their care (Knaul et al, 2018). 
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The Proposed Solution 
Unique challenges such as the palliative care situation in Africa require innovative solutions, 
and such an intervention has been created to address multiple problems in this crisis. Originally 
conceived by a non-profit organization known as Hospice Africa Uganda (HAU) and later refined 
and expanded by the American Cancer Society (ACS), the program revolves around the concept of 
in-house production of oral morphine solution (Merriman and Harding, 2010). Morphine powder is 
ordered from a supplier and stored offsite in a secure location. When needed, small shipments are 
imported to the country and immediately mixed with water, preservative, and food coloring (to 
indicate product concentration), and then distributed by trained healthcare providers (Merriman and 
Harding, 2010). The end product is inexpensive, has a fairly long shelf-life, is difficult to divert, is 
easy to train on administration, and, importantly, is highly effective at treating pain. In addition to 
improving supply, the HAU and ACS partnership has also focused on prescriber education and 
palliative care advocacy efforts, which have raised awareness of the need for palliative care services 
and expanded the base of healthcare workers able to provide them (Merriman and Harding, 2010). 
Methods 
The goal of my capstone project is to examine the impact of an ACS-led initiative to 
improve access to palliative care services (specifically morphine for treatment of pain) in various 
countries in Africa. To do this, I have collected information reported to the International Narcotics 
Control Board (INCB), which is an agency within the United Nations that is tasked with overseeing 
imports and exports of opioids (and other controlled substances) throughout the world. Each year, 
countries are expected to report estimates of national opioid consumption to the INCB in order for 
the INCB to then establish yearly ordering limits. 
 Accessing these reports from the INCB website (www.incb.org), I collected morphine 
consumption data for 55 African countries from 2007 to 2016 (the most recent report available on 
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the website). Of these 55 countries, 7 were listed as having failed to report across all years, 2 
countries failed to report on morphine consumption specifically, and 5 countries lacked data for 
other variables in the analysis. This resulted in a total of 41 countries for my analysis. A complete 
listing of included and excluded countries may be found in Appendix A. 
It should be noted that there is considerable variability in how countries choose to report 
opioid consumption, which requires careful consideration of the best way to handle the available 
data. For example, it is very common for countries to report consumption as merely a reflection of 
imports, and whatever quantity they order for the year they immediately report as “consumed.” 
Given utilization and ordering patterns, it is instead more likely that a quantity of morphine ordered 
in a given year may instead last several years before more must be ordered, or it may even expire 
without being used at all. As previously mentioned, there are also many African countries that fail to 
submit any report at all in a given year, which would technically disallow them from ordering any 
opioids in that year, but to which international organizations often turn a blind eye because 
utilization and ordering are so low. There are also countries that report quantities so low that the 
INCB simply refers to them as “<0.5 kg,” and yet others that actually report “0 kg” of consumption 
(likely an inaccurate statement but again related to the tendency to link ordering to consumption). 
Because of all of these considerations, I made several decisions in my handling of the data: 1) I listed 
all “<0.5 kg” reports as 0.25 kg; 2) I converted all “no reports” to 0 kg; and 3) I took 3-year averages 
of opioid consumption data (e.g. “2008 morphine consumption” is the average of reported 
consumption for 2007, 2008, and 2009). 
After contacting ACS, I also obtained dates for when they began operations in 5 separate 
countries: Uganda, Kenya, Swaziland, Nigeria, and Rwanda. Using this information, I created a 
binary “yes/no” variable with “0” representing a year in which the ACS program was not present 
and a “1” to represent a year in which the initiative was operational. I further learned that they have 
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partial involvement in 4 other countries (Botswana, Democratic Republic of Congo, Togo, and 
Benin), where they are providing “technical support” as these countries create and implement their 
own palliative care initiatives. In these scenarios, ACS has offered themselves as a resource to 
answer questions and give advice. In none of these 4 cases was technical support initiated prior to 
2017, and so there is no direct impact on the years considered in the analysis, but it is worth noting 
that there are likely some differences in morphine consumption behaviors in these countries. 
Using morphine consumption as the dependent variable, I analyzed the presence of the ACS 
program as the explanatory variable with the effect determined by 1) a pooled, time series regression 
accounting for the fixed effects of an individual country, and 2) a difference-in-differences (diff-in-
diff) analysis. Other variables included in the analysis are codeine consumption, which was also 
obtained from the INCB reports and converted to 3-year averages as explained above; population 
data (in millions of people), as obtained from the United Nations yearly estimates on population; a 
corruption perceptions index (CPI), created and published by Transparency International; and an 
education index, produced by the United Nations Development Program. 
Codeine Consumption 
 Codeine is a lower potency opioid that is internationally scheduled in a less restrictive 
category than morphine or other stronger opioids. In addition to its use as a treatment for pain, it is 
also commonly found in cough syrups. Because of its lower level of restriction and its multifaceted 
uses, it is easily the most commonly used opioid worldwide (Davis and Anderson, 2010). In spite of 
its widespread use, it is actually much more difficult than morphine to dose correctly because of 
genetic variations in liver metabolism, and so it is not commonly used for treatment of severe pain 
as would be the case in palliative care (Dean, 2012). I have chosen to include it in this analysis to 
serve as a “baseline level” of prescribing behaviors against which to compare morphine prescribing 
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behaviors (i.e. Are prescriptions for pain generally increasing throughout the country, or is morphine 
alone increasing because of the effect of the initiative?). 
Population Data 
 United Nations’ yearly population estimates were accessed from their website at 
https://population.un.org/wpp/Download/Standard/Population/.  Population numbers were 
included because it would be expected that more populous countries would consume more 
morphine. It should be noted that their report did not contain estimates for the year 2016, and so I 
chose to use Microsoft Excel to estimate a population value for 2016 based off of trends. 
Corruption Perceptions Index (CPI) 
 The Corruption Perceptions Index (CPI) was created in 1995 by an organization known as 
Transparency International. Per the website, (www.transparency.org/research/cpi/overview) its goal 
is to bring to light the corrupt behaviors of certain governments and thereby hold them accountable 
to the international community. The index is compiled by collecting data from several surveys 
distributed to various organizations (e.g. international banks, think tanks, watchdog organizations, 
research groups, etc.). These surveys all contain questions dealing with the actions of governments 
and their potential abuse of power. Depending on the year, there are around a dozen possible 
surveys that may be completed for an individual country, although not every survey will be 
completed for every country. Results are normalized to a scale of 0 to 10 (or 0 to 100, starting in 
2012) and averaged, and this average comprises a country’s CPI score. 
I chose to include this index (with appropriate adjustments to account for the scale change 
in 2012) because the morphine consumption values reported to INCB, in addition to reflecting 
prescribing behaviors, are also indicative of government awareness of palliative care and their 
involvement in it. Healthcare throughout much of Africa is nationalized, so it would be reasonable 
to presume that a government’s level of corruption might impact the provision of quality care to its 
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citizenry. It should be noted that Swaziland did not participate in the CPI for the years 2015 and 
2016, although they resumed participation in 2017 with a score of 3.9. Given that their 2014 score 
was 4.3, I chose to assign 2015 and 2016 scores of 4.1 and 3.9, respectively. 
Education Index 
 The United Nations Development Programme’s Human Development Report Office 
(HDRO) calculates a yearly education index to reflect the level of education of a country’s 
population. It takes into consideration both the average years of schooling of the adult population 
and the expected years of schooling for children. These numbers are converted to an index by 
scaling against corresponding maxima, and averaged together to form the overall education index. In 
practical terms, an index score below 0.5 would suggest that, on average, adults and children are 
receiving less than half the amount of education that is desirable or possible. Because morphine 
consumption is also a reflection of patient attitudes toward their healthcare, I chose this index in an 
effort to reflect the education of the population and thus their ability to understand and accept 
treatment. 
Results 
This analysis was performed to compare the expected trajectory of morphine consumption 
against actual consumption in countries where the ACS program was implemented. A summary of 
the information used in the analysis is provided in Table 1 below. 
Table 1. Summary of Data 
Variable Mean Std. Dev. Min Max 
Morphine Consumption (kg) 12.6 62.6 0 573 
Codeine Consumption (kg) 211 701.8 0 4829 
Corruption Perceptions Index 3.2 1.1 1.1 6.5 
Education Index 0.46 0.13 0.16 0.73 
Population (millions) 25.3 31.1 0.49 181 
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Time Series Regression with Fixed Effects 
Results of the time series regression are found in Table 2. 
Table 2. Time Series Regression, Effects on Morphine Consumption  
Variable name Coefficient P-value 95 % Conf. Interval 
Presence of ACS program 1.33 0.849 (-12.46  ̶  15.13) 
Codeine Consumption -0.044 <0.001 (-0.058  ̶  -0.030) 
Corruption Perceptions Index -7.04 0.050 (-14.08  ̶  -0.001) 
Education Index 13.97 0.842 (-123.73  ̶  151.67) 
Population 1.96 0.001 (0.81  ̶  3.11) 
  
 Several observations can be made from the results: First, the ACS program does not appear 
to have a statistically significant effect on morphine consumption, at least as reported by the country 
to the INCB, although the trend appears to be towards increased consumption. Three variables did 
demonstrate statistically significant effects: codeine consumption, which actually tended to decrease 
consumption of morphine (likely by substitution effect); population, where having a more populous 
country would, as expected, lead to higher consumption of morphine; and having a higher 
corruption perceptions index, which led to a sizeable decrease in morphine consumption. 
Diff-In-Diff Analysis 
 In this analysis, countries not implementing the ACS program were used to form a “control 
group,” indicating general trends in morphine consumption across the African continent. Countries 
where the program was implemented then formed the “treatment group,” and comparisons could 
then be made between pre- and post-treatment time periods (comparing treatment to control). The 
results of the diff-in-diff analysis are found in Table 3. 
Table 3. Diff-in-Diff Analysis, Effect on Morphine Consumption 
Variable name Coefficient P-value 95 % Conf. Interval 
Presence of ACS program 0.39 0.956 (-13.50  ̶  14.28) 
Codeine Consumption -0.044 <0.001 (-0.058  ̶  -0.030) 
Corruption Perceptions Index -6.86 0.079 (-14.52  ̶  0.81) 
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Education Index -105.12 0.292 (-300.95  ̶  90.72) 
Population 1.73 0.005 (0.52  ̶  2.94) 
 
 The results are very similar to the previous time series regression, with the exception that the 
effect of CPI is no longer statistically significant, and the coefficients are generally smaller in 
magnitude.  
Graphs of Treatment Countries 
Graphical depictions of this analysis comparing the control group average to individual 
treatment countries provides visual insight into a potential treatment effect. Note that for each of 
the following figures, the vertical axis is scaled to the treatment country on the left side, and to the 
control average on the right side. The dashed line indicates the year of ACS program 
implementation. Also, the numbers depicted for morphine consumption are 3-year averages as 
previously described. 
Kenya 
The ACS program was implemented in Kenya in 2010, and from Figure 1 there appears to 
have been a significant lag effect. This could have been due to the initiative itself being in its very 
early stages, and therefore requiring some time for training, facility location and preparation, 
identification of target patient population, etc. It should also be noted, however that 2011-2014 were 
all “no report” years for Kenya, after which a very large quantity was reported in 2015 (potentially a 
“catch-up” report accounting for several years of missing data?). It would be interesting to see if this 
trend of increased consumption continued in subsequent years, but the latest available data on the 
INCB website is from 2016. 
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Figure 1. Kenya vs Control 
 
 
Nigeria 
Nigeria officially partnered with ACS beginning in 2012, and as depicted in Figure 2, there 
appears to have been an initial surge in consumption. This effect tapers off in 2015, however, 
blunting the overall post-treatment effect and calling into question the sustainability of the initiative. 
It should be noted that Nigeria is Africa’s most populous country, so these morphine consumption 
numbers being well below the continent’s average is discouraging and are most certainly insufficient 
to meet needs. 
 
  
0
2
4
6
8
10
12
14
16
18
20
0
5
10
15
20
25
30
35
2008 2009 2010 2011 2012 2013 2014 2015
A
nn
ua
l M
or
ph
in
e 
C
on
su
m
pt
io
n 
(k
g)
Year
Kenya
Control Avg
Page | 15  
 
Figure 2. Nigeria vs Control 
 
 
Rwanda 
Rwanda implemented the ACS program during 2011 and seems to have experienced a lag in 
program implementation, similar to Kenya, as depicted in Figure 3. Unlike Kenya and Nigeria, 
however, the effect does not appear to reach a saturation point and consumption grows throughout 
the time period in question. It should be noted that, from the national level, Rwanda also became 
the first African country to establish a national policy on palliative care in 2011 (Krakauer et al, 
2018). This underscores the importance of government involvement in achieving success with the 
ACS initiative, particularly when healthcare is run from the national level. 
 
0
2
4
6
8
10
12
14
16
18
20
0
0.5
1
1.5
2
2.5
3
3.5
2008 2009 2010 2011 2012 2013 2014 2015
A
nn
ua
l M
or
ph
in
e 
C
on
su
m
pt
io
n 
(k
g)
Year
Nigeria
Control Avg
Page | 16  
 
Figure 3. Rwanda vs Control 
 
 
Swaziland 
The ACS initiative was implemented in Swaziland starting in 2012, and as depicted in Figure 
4, it appears to have had an impact from the start. Prior to program implementation, Swaziland had 
never submitted a report to the INCB, and in reality did not start submitting reports until 2014 
(again, likely a “catch-up” report). Because of this, it is difficult to actually gauge the effect in early 
years of program implementation, but it does appear to have eventually reached the level of affecting 
government reporting. 
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Figure 4. Swaziland vs Control 
 
 
Uganda 
Uganda represents the most problematic country to analyze, because in actuality it was the 
country that pioneered the oral morphine solution approach, as early as 1993 (Merriman and 
Harding, 2010). It should be noted that before 2010, Uganda was already consuming morphine at 
relatively high levels, and so ACS involvement probably served more to bolster already existing 
resources and infrastructure. This seems to be verified by the appearance of Uganda’s morphine 
consumption in Figure 5, which fluctuates but generally stays around 17 kg. Bearing this theory in 
mind, I chose to repeat the previous analyses (time series regression and diff-in-diff analysis) 
utilizing all of the same data but with Uganda excluded. The results are seen in Tables 4 and 5. 
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Figure 5. Uganda vs Control 
 
Table 4. Time Series Regression with Uganda Excluded 
Variable name Coefficient P-value 95 % Conf. Interval 
Presence of ACS program 5.08 0.514 (-10.22  ̶  20.38) 
Codeine Consumption -0.045 <0.001 (-0.059  ̶  -0.030) 
Corruption Perceptions Index -7.76 0.035 (-14.95  ̶  -0.56) 
Education Index 15.90 0.823 (-123.57  ̶  155.37) 
Population 2.01 0.001 (0.83  ̶  3.18) 
 
Table 5. Diff-in-Diff Analysis with Uganda Excluded 
Variable name Coefficient P-value 95 % Conf. Interval 
Presence of ACS program 5.09 0.515 (-10.27  ̶  20.44) 
Codeine Consumption -0.045 <0.001 (-0.060  ̶  -0.031) 
Corruption Perceptions Index -7.81 0.051 (-15.63  ̶  0.02) 
Education Index -118.16 0.245 (-317.88  ̶  81.56) 
Population 1.74 0.005 (0.52  ̶  2.97) 
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The results of this analysis seem to confirm that Uganda was influencing the ability to 
observe a treatment effect. While the ACS program is still not demonstrating a statistically 
significant effect, the p-value is much lower than in the previous analyses and the coefficient is much 
greater in magnitude. 
Discussion 
Assessing the Analysis 
Although the ACS program did not appear to demonstrate statistical significance with the 
data available, it is worth discussing what may have prevented such an outcome. One potential 
problem is the small number of instances of program implementation: Of the 41 countries included 
in the analysis, only 5 of them (12.2%) fully implemented the program, and for a total of only 30 
years of demonstrated experience out of a possible 410 years (7.3%). From among the treatment 
countries, Uganda presents an interesting case to analyze for the fact that it had a primitive version 
of the ACS program prior to 2010. It is very possible that 2010 represented less of a change and 
more of a bolstering of the program already in place. Indeed, looking at the graph of Uganda’s 
morphine consumption, it would appear to be in more of a plateau phase than an upward slope. 
This likely diminished the observed effect of program implementation. Removing Uganda from the 
equation does noticeably change the results, but accentuates the problem of having too few 
instances of program implementation by narrowing the treatment countries to four. Additionally, it 
is difficult to account for the countries partially implementing the program (Benin, Botswana, DRC, 
Togo) by receiving technical assistance from ACS. 
The idea of a treatment and control group in this particular analysis is also somewhat of a 
flawed concept. In speaking with individuals at ACS, there was a calculated process involved in 
choosing some of the initial countries where the program was implemented. Generally speaking, 
they selected countries with relative stability, cooperative governments, and a willingness to 
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implement the program, indicating a mentality already primed for program implementation. In other 
words, the treatment group was not by any means randomly selected, and there are likely inherent 
differences between treatment and control countries. I attempted to account for this by including 
the CPI variable and including regionally similar countries in the analysis, but it should be noted that 
this is far from a randomized experiment. 
 All things considered, the most significant weakness in this analysis lies in the morphine 
consumption data itself. As mentioned previously, there is substantial variability in how the data is 
reported, resulting in a lack of confidence that the numbers in the report accurately reflect 
consumption. The potential bias resulting from countries failing to report anything presented a 
considerable challenge because of not knowing how to treat the information. The intended purpose 
in the creation of INCB was to prevent abuse and diversion of controlled substances, and in 
countries where use is so low (as is the case in much of Africa) the organization tends to take a 
hands off approach, allowing the countries to import their small quantities of opioids but without 
close supervision. As a result, accountability for data reporting is extremely low and consequences 
for a failure to report are non-existent. In all there were 126 incidences of a failure to report out of a 
possible 410 opportunities to report. Countries failing to report across the entire 10 years observed 
were, of necessity, excluded from the dataset, but this again potentially introduces bias into the 
analysis. 
All of this led me to the calculation of 3-year consumption averages to better reflect what I 
believe may actually be occurring. However, this choice also likely diluted out the effect of any 
sudden spike in opioid consumption at the time of program implementation. Ideally, more robust 
consumption data would be required to obtain a high-confidence analysis and result, such as 
compiled prescription data from physician practice sites or hospice programs. Considering that the 
focus of this initiative is on improving palliative care, what would be even more useful would be 
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knowledge of the diagnoses for which an opioid is being prescribed, a count of untreated cases of 
painful suffering, and quantification of opioid use not related to surgery or childbirth. As medical 
data systems advance and improve in Africa, it will be increasingly important to include such 
opportunities for data collection to better assess quality of care and outcomes. 
This problem with the unavailability of high-quality data is a frustration for researchers in 
many parts of the world, but it is particularly apparent in the context of African research. Ideally for 
this analysis, I would have liked to include some measure of disease burden to represent the need for 
palliative care, which I believe would influence the amount of morphine consumption. When 
searching through published data, however, I quickly discovered that there is simply no information 
being collected or reported throughout the vast majority of the African continent. A yearly 
publication known as GLOBOCAN reports the incidence of cancer for countries around the world, 
but they readily admit that there is simply no data available for nearly all of Africa – in 2012, there 
were only 2 countries (Egypt and South Africa) with any cancer data to speak of (Ferlay et al, 2015). 
Much of this problem stems from the lack of access to care, or a lack of effort to access the care that 
is available, and therefore many cases of disease go undiagnosed. It would also appear, however, that 
even in cases where care is administered, there is a lack of detailed documentation of the encounter. 
This sort of information will be key to Africa’s ability to recognize and address problems such as this 
crisis of palliative care that would otherwise go undetected. 
The Effect of South Africa 
 It is worth noting the impact of South Africa on this analysis. As noted in Table 1 in which 
the data is summarized, the average morphine consumption for the continent is around 12 kg per 
year. Table 1 further reveals that the maximum value for morphine consumption was 573 kg, which 
occurred in South Africa in 2011 (note that this is actually a value based on a 3 year average – the 
actual number reported to INCB that year was 962 kg, but which was diluted out by lower numbers 
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in 2010 and 2012). Compared to the other countries in the analysis, South Africa is an extreme 
outlier, which strongly impacted the shape of the curve for the control group, as depicted in Figure 6 
(note the extreme differences in scale of the vertical axis between the control average and South 
Africa’s consumption). 
Figure 6. Comparison of South Africa and Control Group 
 
  
When South Africa is excluded from the control group, the shape of the curve changes 
dramatically both in magnitude and shape, as depicted in Figure 7, and a summary of the data 
without South Africa reveals a changed dataset in terms of opioid consumption (Table 6). 
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Figure 7. Control Averages, with and without South Africa 
 
 
Table 6. Summary of Dataset without South Africa 
Variable Mean Std. Dev. Min Max 
Morphine Consumption (kg) 3.2 6.8 0 48.7 
Codeine Consumption (kg) 121 400.3 0 2980 
Corruption Perceptions Index 3.2 1.1 1.1 6.5 
Education Index 0.45 0.12 0.16 0.73 
Population (millions) 24.6 31.2 0.49 181 
 
 It was my desire to remove South Africa from the analysis altogether, but doing so presented 
several problems in and of itself. In terms of its consumption behavior, South Africa more strongly 
resembles European levels, and of all of the countries in the analysis, its data is the most believable 
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and likely the most accurate. Removing South Africa from the dataset accentuates the problem of 
having far too many countries with poor reporting. Furthermore, it leaves mostly countries with very 
low levels of consumption, making changes in consumption trends more nuanced and difficult to 
observe. These concerns were verified in my attempts to perform analyses without South Africa, 
which left virtually every variable as statistically insignificant, as shown in Table 7. 
Table 7. Time Series Regression, without South Africa 
Variable name Coefficient P-value 95 % Conf. Interval 
Presence of ACS program -0.044 0.980 (-3.49  ̶  3.40) 
Codeine Consumption -0.003 0.281 (-0.007  ̶  0.002) 
Corruption Perceptions Index 0.36 0.666 (-1.27  ̶  1.99) 
Education Index -18.56 0.244 (-49.88  ̶  12.76) 
Population 0.63 <0.001 (0.35  ̶  0.91) 
 
 I chose to include South Africa mainly because of the quality of the data it provided. While I 
acknowledge that it strongly influenced the outcome, I am somewhat reassured by a careful 
comparison of the different averages depicted in Figure 7. In general, the trends are at least similar: 
the lowest point is in 2008, and there is a local maximum in 2011, a local minimum in 2013, and an 
upward trend in 2014 through 2015. 
Recommendations and Future Directions 
 The results of this research do not allow me to confidently recommend the program for 
widespread implementation. In no case did this concept spiral out of control or result in systemic 
overuse or misuse of morphine. Thus the risk of harm appears to be minimal, particularly in the 
African context, where opioids are so woefully underutilized. There are currently too few instances 
to truly gauge the full effect of the program, and therefore it is worth further experimentation to 
observe possible outcomes. As previously mentioned, improved data collection and reporting will be 
important going forward. 
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 From my research on this situation, I believe that the most significant roadblock to 
improving palliative care in Africa exists with the doctors themselves. While my experiment was 
limited to available data and focused more on a measurement of program outputs (i.e. morphine 
consumption), I feel that it would be more useful to determine program outcomes. Specifically, is 
the training being administered by the ACS program having an impact on prescriber attitudes and 
behaviors? This could be achieved by administering a survey to program participants, both prior to 
training to determine baseline attitudes and upon completion of the program. The survey should 
gauge attitudes toward opioids, knowledge of situations where it is appropriate to prescribe them, 
knowledge of how to dose them, and knowledge of necessary monitoring parameters. This is 
important because no matter how much morphine supply is increased, it will not have an impact 
unless prescribers are willing to utilize what is made available.  
 It is also important to determine government attitudes towards palliative care. The majority 
of African countries administer healthcare from the national level, and much of the healthcare 
provided is driven by standard treatment guidelines (STGs) which essentially serve as treatment 
protocols describing how to respond to a particular clinical scenario. An interesting topic of study 
would be to determine how many countries in Africa have an established palliative care STG that 
includes morphine for the treatment of severe pain. 
 A great deal of work remains to be done in regards to this crisis. This capstone paper 
represents a first attempt at program evaluation and hopefully serves to shed light on an 
unacceptable situation that merits immediate attention. This is a humanitarian catastrophe that has 
led to unnecessary suffering for many thousands, if not millions, of Africans who are left to die 
ignominious deaths. The resources exist to rectify this situation in an affordable manner, but it will 
require the concerted efforts of international organizations, governments, and healthcare providers 
to adequately address the problem. 
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Appendix A 
Countries included in the analysis: 
 Algeria 
 Angola 
 Benin 
 Botswana 
 Burkina Faso 
 Burundi 
 Cameroon 
 Cape Verde 
 Chad 
 Congo, Democratic Republic of 
Cote d’Ivoire 
 Egypt 
 Eritrea 
 Ethiopia 
 Gabon 
 Ghana 
 Kenya* 
 Lesotho 
 Libya 
 Madagascar 
 Malawi 
 Mali 
 Mauritania 
 Mauritius 
 Morocco 
 Mozambique 
 Namibia 
 Niger 
 Nigeria* 
 Rwanda* 
 Senegal 
 Sierra Leone 
 South Africa 
 Sudan 
 Swaziland* 
 Tanzania 
 Togo 
 Tunisia 
 Uganda* 
 Zambia 
 Zimbabwe
* - Indicates a treatment country 
 
 
Countries excluded from the analysis: 
 
• Due to a failure to report across all years of the analysis (2007-2016): 
o Central African Republic, Djibouti, Equatorial Guinea, Gambia, Republic of Congo, 
Somalia, South Sudan 
• Due to a failure to report morphine consumption across all years of the analysis (2007-2016): 
o Guinea, Liberia 
• Due to an inability to obtain other data for the analysis: 
o Ascension Island, Saint Helena, Sao Tome and Principe, Seychelles, Tristan da 
Cunha 
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